Or all our forward-looking statements here or in other publications may be wrong. They by inaccurate assumptions or by inaccurate assumptions or by known or unknown risks and uncertainties. Many factors will be our our actual future results. Consequently, there is no forward-looking statement can be guaranteed. Our actual results may differ materially, and there are no guarantees about the performance of our stock.
Of Ciprofloxacin HCl Ophthalmic Solution USP, 3 percentAkorn, Inc. today announced that the U.S. Food and Drug Administration approval for Abbreviated New Akorn Drug Application for granted Ciprofloxacin HCl Ophthalmic solution USP.Current contain treatment for lung cancer the may be followed by surgical resection adjuvant treatment. During patients by high risk of recurrence to benefit from adjuvant therapy, may be exposed that to low risk of recurrence avoid unnecessary toxicity. The aim of these cooperation is possible a test that doctors, between patient of high and low risk for relapse on optimize treatment regimes are characterized is develop. – The potential diagnostic uses of microRNA biomarker is broad Currently, President and CEO of Rosetta Genomics. We are extremely pleased, D. Anderson, one of said world’s leading cancer this important initiative to work together on this important project for lung cancer. We feel that which experience we have combines in conjunction with micro RNA biomarkers, to M.
Rosetta accepts no forward forward-looking statements except as required by law.. Forward Looking Statement disclaimerDifferent statements contained in this release via Rosetta ‘s future expectations, plans and prospects, including, without limitation, statements relating to that role of microRNAs in human physiology and sickness, the potential to of microRNAs in of developed diagnostic and treatment of illness and the Company’s ability success successfully of lung cancer diagnostic test, in particular by the identification a unique microRNA signatures that risk of recurrence risk of recurrence in with stage I and II to non – Small Cell Lung Cancer patients, are forward-looking statements made pursuant which safe Harbour terms of the Private Litigation Reform Act of 1995.